Researchers at Tokyo University of Science successfully synthesized tanzawaic acid B in large amounts, paving the way for new antibiotic development. The breakthrough method could lead to creation of various compounds for pharmaceuticals, including new antibiotic candidates.
A team of researchers led by Laura-Isobel McCall and Zhibo Yang is using single-cell mass spectrometry to investigate the role of intracellular drug concentration in antimicrobial treatment failure.
A recent study published in Neurology suggests that starting treatment for multiple sclerosis (MS) soon after the first signs of the disease may lead to a lower risk of disability later. Researchers found that patients who received treatment within six months of symptom onset had a significantly lower risk of developing severe disabili...
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
Researchers at Northwestern University discovered that antipsychotic drugs interact with a different neuron type than scientists originally believed, which could lead to better treatments for schizophrenia. The study's findings suggest that the effect of antipsychotics on dopamine receptors has little bearing on their efficacy in humans.
Conventional psychotherapeutic approaches for women with late-stage gynaecological cancers take too long and require too much stamina. Psilocybin-assisted psychotherapy has shown promise in treating anxiety, depression, and end-of-life distress with rapid and sustained effects.
SourceBMJ Group·JournalInternational Journal of Gynecological Cancer·TypeCommentary/editorial·DateJul 18, 2023
Researchers at Tokyo Metropolitan University have discovered that 5-aminolevulinic acid can selectively boost Complex II and IV to counteract Complex I deficiency, a common cause of mitochondrial disorders. This finding offers new hope for the development of treatments for debilitating conditions such as MELAS syndrome.
The Brigham team designed nanoparticles that deliver stimulator of interferon genes (STING) agonists to immune cells, training them to recognize and eliminate future tumors. This approach eradicates active tumors in mice with melanoma, colon cancer, and breast cancer, while preventing future tumor formation.
Researchers at Mass General Cancer Center treated 16 patients with a BRAF/MEK inhibitor, resulting in a 91% reduction in tumor size and complete response in all patients who received one or more cycles of therapy. The treatment showed unprecedented success in targeting brain tumors using precision medicine approaches.
Researchers at Columbia University Irving Medical Center have discovered that an experimental eye drop treatment can reduce swelling and improve blood flow in the retina of mice with retinal vein occlusion, a common eye disease affecting up to 2% of people over age 40. The study found that the eye drops prevented neurons from deteriora...
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Mass General Cancer Center researchers have pinpointed the APOBEC3A protein as a primary driver of drug resistance in non-small-cell lung cancer. The study reveals that this protein causes mutations and accelerates tumor growth, making it a promising target for new therapies.
A randomized clinical trial found that treatment with these biologics showed no significant difference in time to recovery compared to placebo for patients hospitalized with COVID-19 pneumonia. The study's results suggest that alternative treatments may be needed for this patient population.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Fewer than half of new drugs approved for multiple indications in the US and Europe between 2011 and 2020 offered significant benefits over existing treatments. A study found that supplemental approvals were substantially less effective, suggesting a need to clearly communicate this information to patients and reflect it in drug prices.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
Researchers at the University of Pittsburgh School of Medicine found no evidence that prescription stimulant treatment in childhood increases the risk of substance use disorder (SUD) later in life. The study, published in JAMA Psychiatry, suggests that stimulants are an effective treatment for ADHD with few side effects.
The Multidisciplinary Molecular Tumour Board (MTB) has been shown to improve treatment response rates for patients with advanced solid cancer, with 64% of patients benefiting from the MTB-guided approach. The board provides a systematic precision oncology strategy for treatment selection, combining expertise in multiple disciplines.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
Researchers have developed a sustainable and scalable method to produce therapeutic oligonucleotides, which have the potential to treat various diseases. The new approach uses polymerases to amplify a catalytic DNA template in a single step, addressing challenges associated with current methods.
Scientists create optically controllable liposomes called LiDLs, which can selectively release contents inside cells upon exposure to acidic pH induced by green light. The researchers demonstrated that LiDLs efficiently deliver substances without causing side effects, showcasing exceptional extracellular stability.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
The study investigates the effects of DPDT on human colon cancer HCT116 cells and non-tumorigenic MRC5 fibroblasts. The results show that DPDT preferentially targets HCT116 cells, inducing apoptosis and G2/M cell cycle arrest, likely through DNA topoisomerase I poisoning.
A randomized controlled trial found that time-restricted eating produced similar weight loss results to traditional calorie counting in a racially diverse population of adults with obesity. Participants who engaged in 8-hour time-restricted eating had improved insulin sensitivity compared to those in the control group.
The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.
A new molecular compound has been identified that can activate latent HIV-1 in cells, showing promise for HIV treatments. Researchers found that this compound, YSE028, can reactivate latently infected cells and induce cell death, potentially leading to a complete cure for HIV.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
A novel study found that honokiol promotes healing of rotator cuff injury and may be an effective treatment for humans. The study suggests that SIRT3 activation plays a protective role in alleviating aging-induced fibrocartilage degeneration and promoting rotator cuff healing.
Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
Scientists have discovered that dimethylfumarate can block blood clotting during infection, potentially treating life-threatening DIC and severe COVID-19. The mechanism involves blocking interferon production, which promotes tissue factor releases.
Researchers at IUPUI will lead two grants totaling $11.7 million to discover a drug treatment for hydrocephalus, a condition commonly associated with traumatic brain injury. The studies aim to test the effectiveness of treatments for three types of hydrocephalus and may lead to a new treatment option.
Fruquintinib has shown statistically significant improvement in overall survival and progression-free survival rates for patients with metastatic colorectal cancer. The median survival rate was 7.4 months, with a 34% reduction in death compared to the placebo group.
The Better Together trial partners with community organizations and sites to provide buprenorphine treatment, reducing distance for patients and offering peer support in familiar environments. Researchers aim to address barriers such as stigma, misunderstandings about addiction, and bias against certain treatments.
Researchers have developed a sonodynamic cancer immunotherapy based on semiconducting polymer nanoparticles that can be activated by ultrasound, effectively treating orthotopic pancreatic cancer in mouse models. The treatment induces immunogenic cell death and kills cancer cells without causing excessive immune responses.
SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJun 14, 2023
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
Scientists at RIKEN Center for Brain Science find that somatic mutations in six genes lead to intracranial aneurysms, which can be blocked with a drug. The study establishes the first non-surgical animal model of intracranial aneurysm and provides a potential new treatment option.
The use of psychedelics in mental health treatment is gaining traction, but concerns about patient safety and regulation need to be addressed. Psychedelic-assisted therapy shows promise in treating conditions like depression and PTSD, but more research is needed on dosages, settings, and guidelines.
A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.
A new study published in Journal of Leukocyte Biology found that age and sex differences contribute to increased inflammation in older female mice. The research team discovered that immune cells entering areas where they shouldn
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers from UTEP School of Pharmacy are exploring a new treatment for vascular dementia using the NIH grant to study the biological triggers behind the condition and test the effectiveness of candidate drug ZT-1a. The treatment aims to prevent cognitive impairments in dementia patients.
A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers at the National Human Genome Research Institute identified a potential treatment for disabling pansclerotic morphea, a severe inflammatory disease. They found that patients with the disorder have an overactive STAT4 protein and significantly improved symptoms with ruxolitinib, a JAK inhibitor.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
A study by Japanese researchers identifies the involvement of angiotensin II-AT1 and prostaglandin E2-EP1 systems in high-salt-induced hypertension and emotional/cognitive impairment, offering potential therapeutic targets for dementia prevention.
Two researchers will receive $1 million each for their five-year studies on new medication-based approaches to repair damaged aortas, as well as the effects of exercise on healing heart muscle and brain tissue after a heart attack or stroke. The American Heart Association's Merit Award supports innovative research with high impact.
Researchers developed a novel hybrid protein complex by binding lysozyme to copper for enhanced reactive oxygen species (ROS) removal. The CuST@lysozyme hybrid protein showed high SOD activity and stability in biological fluids, paving the way for its therapeutic applications.
Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.
Researchers at Weill Cornell Medicine have successfully converted human stomach stem cells into insulin-secreting cells, offering a promising approach to treating type 1 and severe type 2 diabetes. The transplants reversed disease signs in mouse models, suggesting good durability.